Monoclonal antibody 5e9 for recognizing human r9AP and use thereof

WO2026138728A1PCT designated stage Publication Date: 2026-07-02SUN YAT SEN UNIVERSITY CANCER CENTER (CANCER HOSPITAL AFFILIATED TO SUN YAT SEN UNIVERSITY CANCER RESEARCH INSTITUTE OF SUN YAT SEN UNIVERSITY)
View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
SUN YAT SEN UNIVERSITY CANCER CENTER (CANCER HOSPITAL AFFILIATED TO SUN YAT SEN UNIVERSITY CANCER RESEARCH INSTITUTE OF SUN YAT SEN UNIVERSITY)
Filing Date
2025-12-22
Publication Date
2026-07-02

Smart Images

  • Figure PCTCN2025144284-FTAPPB-I100001
    Figure PCTCN2025144284-FTAPPB-I100001
  • Figure PCTCN2025144284-FTAPPB-I100002
    Figure PCTCN2025144284-FTAPPB-I100002
  • Figure PCTCN2025144284-FTAPPB-I100003
    Figure PCTCN2025144284-FTAPPB-I100003
Patent Text Reader

Abstract

The present invention relates to the technical field of antibodies. Disclosed are a monoclonal antibody 5E9 for recognizing a human R9AP and a use thereof. The monoclonal antibody or an antigen-binding fragment thereof has a high affinity to an R9AP and can significantly inhibit the infection of EB virus (EBV) on epithelial cells and B cells. The antibody can be used for detecting the presence or level of the R9AP in a sample, detecting diseases caused by high expression of the R9AP and preventing EBV infections and / or treating and / or preventing diseases caused by EBV infections.
Need to check novelty before this filing date? Find Prior Art